©2025 Stanford Medicine
A Study of a Levonorgestrel-Releasing Intrauterine System for Long-Term, Reversible Contraception
Not Recruiting
Trial ID: NCT00995150
Purpose
The primary objective of this study is to assess the efficacy of a levonorgestrel-releasing intrauterine system (LNG20) in nulliparous and parous females of child-bearing potential who request long-term, reversible contraception for up to 10 years.
Official Title
A Phase 3, Multi-Center, Open-Label Study of a Levonorgestrel-Releasing Intrauterine System for Long-Term, Reversible Contraception
Stanford Investigator(s)
Paul D. Blumenthal, MD, MPH
Professor of Obstetrics and Gynecology (Gynecology-Family Planning) at the Stanford University Medical Center, Emeritus
Eligibility
Inclusion Criteria:
* Healthy women requesting contraception
* 16-35 years old
* Cohort 36-45 years old
* Sexually active
Exclusion Criteria:
* Currently pregnant, pregnant within 4 weeks prior to study entry or planning pregnancy within 24 months of study entry
* Currently breastfeeding
* Current persistent, abnormal vaginal bleeding
Intervention(s):
drug: LNG20
drug: Mirena
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Kathryn Batham
650-724-7826